127 related articles for article (PubMed ID: 15149348)
1. ACE inhibitor and angiotensin type I receptor antagonist in combination reduce renal damage in obese Zucker rats.
Toblli JE; DeRosa G; Cao G; Piorno P; Pagano P
Kidney Int; 2004 Jun; 65(6):2343-59. PubMed ID: 15149348
[TBL] [Abstract][Full Text] [Related]
2. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats.
Toblli JE; Muñoz MC; Cao G; Mella J; Pereyra L; Mastai R
Obesity (Silver Spring); 2008 Apr; 16(4):770-6. PubMed ID: 18239590
[TBL] [Abstract][Full Text] [Related]
3. Reduced cardiac expression of plasminogen activator inhibitor 1 and transforming growth factor beta1 in obese Zucker rats by perindopril.
Toblli JE; Cao G; DeRosa G; Forcada P
Heart; 2005 Jan; 91(1):80-6. PubMed ID: 15604340
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular protective role of a low-dose antihypertensive combination in obese Zucker rats.
Toblli JE; DeRosa G; Rivas C; Cao G; Piorno P; Pagano P; Forcada P
J Hypertens; 2003 Mar; 21(3):611-20. PubMed ID: 12640256
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibition reduces lipid deposits in myocardium and improves left ventricular function of obese zucker rats.
Toblli JE; Cao G; Rivas C; DeRosa G; Domecq P
Obesity (Silver Spring); 2006 Sep; 14(9):1586-95. PubMed ID: 17030970
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats.
Toblli JE; Cao G; DeRosa G; Di Gennaro F; Forcada P
Am J Hypertens; 2004 Feb; 17(2):172-80. PubMed ID: 14751661
[TBL] [Abstract][Full Text] [Related]
7. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
[TBL] [Abstract][Full Text] [Related]
8. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
[TBL] [Abstract][Full Text] [Related]
9. The angiotensin II receptor antagonist losartan reduces blood pressure but not renal injury in obese Zucker rats.
Crary GS; Swan SK; O'Donnell MP; Kasiske BL; Katz SA; Keane WF
J Am Soc Nephrol; 1995 Oct; 6(4):1295-9. PubMed ID: 8589300
[TBL] [Abstract][Full Text] [Related]
10. Tesaglitazar, a dual peroxisome proliferator-activated receptor agonist (PPAR alpha/gamma), improves metabolic abnormalities and reduces renal injury in obese Zucker rats.
Liao J; Soltani Z; Ebenezer P; Isidro-Carrión AA; Zhang R; Asghar A; Aguilar E; Francis J; Hu X; Ferder L; Reisin E
Nephron Exp Nephrol; 2010; 114(2):e61-8. PubMed ID: 19887847
[TBL] [Abstract][Full Text] [Related]
11. Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system.
Sebeková K; Lill M; Boor P; Heidland A; Amann K
Am J Nephrol; 2009; 29(3):164-70. PubMed ID: 18753741
[TBL] [Abstract][Full Text] [Related]
12. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Blanco S; Vaquero M; Gómez-Guerrero C; López D; Egido J; Romero R
Am J Hypertens; 2005 Apr; 18(4 Pt 1):557-65. PubMed ID: 15831368
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with benazepril and oral adsorbent ameliorates progressive renal fibrosis in uremic rats.
Aoyama I; Shimokata K; Niwa T
Nephron; 2002 Mar; 90(3):297-312. PubMed ID: 11867951
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of blocking renin-angiotensin system on the progression of renal injury in glomerulosclerosis.
Ji Z; Huang C; Liang C; Chen B; Chen S; Sun W
Cell Mol Immunol; 2005 Apr; 2(2):150-4. PubMed ID: 16191423
[TBL] [Abstract][Full Text] [Related]
15. Blockade of the renin-angiotensin and endothelin systems on progressive renal injury.
Cao Z; Cooper ME; Wu LL; Cox AJ; Jandeleit-Dahm K; Kelly DJ; Gilbert RE
Hypertension; 2000 Oct; 36(4):561-8. PubMed ID: 11040236
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial.
Scaglione R; Argano C; Corrao S; Di Chiara T; Licata A; Licata G
J Hypertens; 2005 Mar; 23(3):657-64. PubMed ID: 15716710
[TBL] [Abstract][Full Text] [Related]
17. Significance of exaggerated natriuresis after angiotensin AT1 receptor blockade or angiotensin- converting enzyme inhibition in obese Zucker rats.
Tallam LS; Jandhyala BS
Clin Exp Pharmacol Physiol; 2001; 28(5-6):433-40. PubMed ID: 11380518
[TBL] [Abstract][Full Text] [Related]
18. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
Segura J; Praga M; Campo C; Rodicio JL; Ruilope LM
J Renin Angiotensin Aldosterone Syst; 2003 Mar; 4(1):43-7. PubMed ID: 12692753
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats.
Toblli JE; Cao G; Giani JF; Muñoz MC; Angerosa M; Dominici FP
J Hypertens; 2011 Aug; 29(8):1613-23. PubMed ID: 21720265
[TBL] [Abstract][Full Text] [Related]
20. Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor.
Zhou A; Yu L; Li J; Zhang J; Wang H
Hypertens Res; 2000 Jul; 23(4):391-7. PubMed ID: 10912779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
